Wells Fargo Taps Annexon as Top Biotech Pick on Pipeline Potential

Wells Fargo has designated Annexon as its top pick in the biotechnology sector, highlighting a favorable risk-reward profile and significant upside potential. The investment firm's increased confidence follows recent meetings with Annexon's management and is centered on key upcoming milestones for its lead drug candidates.

Wells Fargo's Bullish Thesis

In a note to clients, Wells Fargo outlined a bull-case scenario with a potential 7-to-8 times upside for Annexon's stock. This optimistic outlook is underpinned by the potential of the company's clinical pipeline and its differentiated approach to treating certain neurodegenerative diseases.

The firm's analysis points to two primary drivers of value in the near and medium term: a late-stage drug for geographic atrophy and a planned regulatory filing for a treatment targeting Guillain-Barré syndrome.

Key Pipeline Catalysts

A central element of Wells Fargo's thesis is Annexon's lead drug candidate, vonaprument, for the treatment of geographic atrophy (GA), a leading cause of blindness. The company remains on track for a pivotal data readout that could reshape the treatment landscape for the disease.

Ad

• Pivotal Data: Top-line results from the Phase 3 trial of vonaprument are expected in the fourth quarter of 2026.
• Market Potential: If successful, Wells Fargo forecasts that vonaprument could become the standard of care, with potential peak sales of approximately $4 billion.
• Mechanism: According to the note, Annexon's management emphasizes the drug's unique mechanism, which works upstream of other inhibitors and focuses on preserving photoreceptor cells essential for vision.

Wells Fargo also identified a nearer-term catalyst with tanruprubart, a treatment for Guillain-Barré syndrome (GBS). Annexon is tracking toward filing a Biologics License Application (BLA) in the U.S. before the vonaprument data release, with clinical data for tanruprubart expected in early Fall.

Analyst Context

Wells Fargo's positive assessment adds to a mixed but active analyst landscape for Annexon. Recently, Needham reiterated a Buy rating and increased its price target to $25. In contrast, Citizens initiated coverage with an Underperform rating, indicating a divergence of opinion among investment analysts on the company's valuation and prospects.